BRAND NAMES
 MECHANISM OF ACTION
Clindamycin binds to the 50S ribosomal subunits of the bacteria, inhibiting protein synthesis.
Topical application in the treatment of acne vulgaris.
Apply a thin film once or twice daily to the clean and dry skin in the area to be treated. Patients responding to Clindamycin (Topical) should show improvement in 8 weeks. Treatment beyond 12 weeks may call for evaluation by the physician.
Clindamycin (Topical) is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin
Clindamycin (Topical) is also contraindicated in individuals with a history of inflammatory bowel disease (including regional enteritis and ulcerative colitis), or a history of antibiotic - associated colitis (including pseudomembranous colitis).
 WARNINGS AND PRECAUTIONS
Clostridium difficile-associated disease:
Clostridium difficile-associated disease (CDAD) has been reported with use of many antibacterial agents, including DALACIN T (clindamycin phosphate topical solution USP 1%). CDAD may range in severity from mild diarrhea to fatal colitis. It is important to consider this diagnosis in patients who present with diarrhea, or symptoms of colitis, pseudomembranous colitis, toxic megacolon, or perforation of colon subsequent to the administration of any antibacterial agent. CDAD has been reported to occur over 2 months after the administration of antibacterial agents.
Treatment with antibacterial agents may alter the normal flora of the colon and may permit overgrowth of Clostridium difficile. C. difficile produces toxins A and B, which contribute to the development of CDAD. CDAD may cause significant morbidity and mortality. CDAD can be refractory to antimicrobial therapy.
If the diagnosis of CDAD is suspected or confirmed, appropriate therapeutic measures should be initiated. Mild cases of CDAD usually respond to discontinuation of antibacterial agents not directed against Clostridium difficile. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial agent clinically effective against Clostridium difficile. Surgical evaluation should be instituted as clinically indicated, as surgical intervention may be required in certain severe cases
 PREGNANCY AND LACTATION
There are no adequate and well-controlled studies in pregnant women. Safety for use in pregnancy has not been established.
Clindamycin (Topical) should not be used during pregnancy unless clearly needed and unless the expected benefits to the mother outweigh any potential risks to the fetus.
Nursing should not be undertaken while a patient is using Topical Clindamycin
 SIDE EFFECTS
Skin dryness/irritation, diarrhea or gastrointestinal symptoms were the most commonly reported medical events
 RELATED LINKS
|Oral antibiotics||Clindamycin (Oral route) • Doxycycline • Erythromycin (Oral route) • Josamycin • Lymecycline • Minocycline • Tetracycline|
|Topical antibiotics||Clindamycin (Topical) • Erythromycin (Topical)|
|Topical retinoids||Adapalene • Tazarotene • Tretinoin|
|Oral retinoids||Isotretinoin (Oral)|
|Oral contraceptives||Estradiol valerate/Dienogest • Ethinyl Estradiol/Cyproterone acetate|
|Topical Antibacterial/Keratolytic||Benzoyl peroxide • Hydrogen Peroxide Cream|
|Topical combination products||Clindamycin/Benzoyl peroxide • Adapalene/Benzoyl peroxide • Clindamycin/Tretinoin • Miconazole/Benzoyl peroxide • Erythromycin/Benzoyl peroxide • Erythromycin/Isotretinoin|